Intensity Therapeutics Inc., a biotechnology company focused on developing novel immune-based cancer therapies, reported its financial results for the first quarter of 2025. The company achieved a net loss of $3.3 million for the three months ended March 31, 2025, a reduction from the net loss of $4.6 million reported for the same period in 2024. This improvement was driven by decreased research and development expenses, which totaled $2.2 million, down from $2.8 million in the previous year. General and administrative expenses also decreased to $1.2 million from $1.9 million in the first quarter of 2024. Intensity Therapeutics highlighted progress in its clinical programs, particularly the INVINCIBLE-4 Study, a Phase 2 trial with eight Swiss sites activated and patient treatments underway. The company received authorization from the European Medicines Agency to initiate the study in France. However, due to cash constraints, the company paused the Phase 3 sarcoma enrollment and site activation until additional funding is secured. Intensity raised approximately $1.9 million net through a public offering to support its ongoing initiatives. As of March 31, 2025, the company's cash and cash equivalents totaled $0.9 million.